Your session is about to expire
← Back to Search
Other
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Phase 2
Waitlist Available
Research Sponsored by Cloudbreak Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Summary
This trial tests an eye drop solution called CBT-008 on patients with certain eye conditions. The drops are absorbed by the eyes to treat the condition directly.
Eligible Conditions
- Meibomian Gland Dysfunction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
IOP Related to Safety
Secondary study objectives
Ocular discomfort score (0-4)
Side effects data
From 2023 Phase 2 trial • 95 Patients • NCT0526138613%
Ocular TEAEs
3%
Non-ocular TEAEs
100%
80%
60%
40%
20%
0%
Study treatment Arm
CBT-008 Ophthalmic Solution Single Dose
CBT-008 Ophthalmic Solution Multi-dose
Vehicle
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental: CBT-008 lower concentrationExperimental Treatment1 Intervention
lower concentration dose
Group II: Experimental: CBT-008 higher concentrationExperimental Treatment1 Intervention
higher concentration dose
Group III: Placebo Comparator: CBT-008Placebo Group1 Intervention
Vehicle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBT-008
2022
Completed Phase 2
~100
Find a Location
Who is running the clinical trial?
Cloudbreak Therapeutics, LLCLead Sponsor
5 Previous Clinical Trials
926 Total Patients Enrolled
1 Trials studying Meibomian Gland Dysfunction
92 Patients Enrolled for Meibomian Gland Dysfunction
Bing Leng, MDStudy DirectorADS Therapeutics, LLC